Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Re: Blocking Oncogenic Ras Signaling for Cancer Therapy

Re: Blocking Oncogenic Ras Signaling for Cancer Therapy We congratulate Adjei (1) on his excellent, comprehensive, and timely review on Ras signaling and the therapeutic implications of blocking this signaling. Perhaps space constraints and a major focus on pharmacologic aspects prevented any discussion of a promising alternative approach to perturbing Ras membrane localization, namely, the diversion of intracellular trafficking by an intracellular antibody (Fig.1). After the initial formal proof of intracellular antibody expression and targeting within the cell in 1990 [see specific publication cited in (2)], this approach was successfully applied to inhibit the function of several intracellular gene products, including p21Ras (2). The p21Ras molecule appears to be particularly sensitive to intracellular antibody-mediated perturbation of its precise localization to the inner face of the plasma membrane, which is crucial for its activity. Thus, anti-Ras intracellular antibodies with cytoplasmic targeting signals have been shown to divert p21Ras from its intracellular location and to address the antigen–antibody complex to the degradative compartment of the cell (3,4). Such intracellular antibodies are effective irrespective of the epitope recognized, the binding affinity, or the mutant status of the Ras protein broadening the spectrum of intracellular antibodies with potential therapeutic usefulness. In an animal model, intratumor injection of anti-Ras intracellular antibodies expressed by an adenoviral vector resulted in a statistically significant tumor regression, despite a low efficiency of in vivo transduction (5). The striking effects on tumors in that study implicate “bystander” mechanisms that amplify the direct inhibitory activity of the intracellular antibodies. Anti-erbB-2 [see references cited in (6)] and p53 (7) intracellular antibodies targeted, respectively, to endoplasmic reticulum and to cytoplasm/nucleus have been validated in several preclinical in vitro models as selective and potent antitumor agents. Furthermore, adenoviral constructs expressing anti-erbB-2 intracellular antibody demonstrated in vivo antitumor activity leading to prolongation of survival in ovarian cancer animal models; these constructs were recently used in a phase I trial to determine the safety profile and gene transfer efficacy after intraperitoneal administration in ovarian cancer patients (6). Rational approaches to engineering antibody regions suited for optimal expression in the desired intracellular compartment, together with improved vector design and strategies that engage bystander mechanisms, hold the promise of enhancing the feasibility and efficacy of intracellular antibody gene therapy. In conclusion, the high level of specificity observed in preclinical studies and the very limited side effects reported in the first clinical application of intracellular antibody technology (6) suggest the value of increased efforts to fully explore the clinical utility of intracellular antibodies directed against p21Ras or other oncogenic molecules. These reagents might be used alone or in combination with other selective inhibitors of oncogene signaling such as farnesyl/geranylgeranyl transferase [see (1) for details] or tyrosine kinase inhibitors. Fig. 1. View largeDownload slide Intracellular antibody expression in mammalian cells. A) The overall intracellular antibody structure, where a heavy chain variable region (VH) of an antibody connected by a linker to its complementary light chain variable region (VL) (single chain Fv = scFv) is tailed or preceded at the C terminus or N terminus, respectively, by a short targeting signal. B) The presence/absence and the amino acid sequences of some common C-terminal and N-terminal targeting signals (2). These signals allow localization of the intracellular antibody to the nucleus (n), endoplasmic reticulum (er), mitochondria (m), or cytoplasm (c), or to be secreted (s), without affecting the specific binding of the scFv to its target molecule. * = The targeting signal for nuclear localization could be either at the C terminus or at the N terminus. C) Scheme of intracellular antibody compartmentalization mediated by the defined targeting signals. Fig. 1. View largeDownload slide Intracellular antibody expression in mammalian cells. A) The overall intracellular antibody structure, where a heavy chain variable region (VH) of an antibody connected by a linker to its complementary light chain variable region (VL) (single chain Fv = scFv) is tailed or preceded at the C terminus or N terminus, respectively, by a short targeting signal. B) The presence/absence and the amino acid sequences of some common C-terminal and N-terminal targeting signals (2). These signals allow localization of the intracellular antibody to the nucleus (n), endoplasmic reticulum (er), mitochondria (m), or cytoplasm (c), or to be secreted (s), without affecting the specific binding of the scFv to its target molecule. * = The targeting signal for nuclear localization could be either at the C terminus or at the N terminus. C) Scheme of intracellular antibody compartmentalization mediated by the defined targeting signals. References 1 Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst  2001; 93: 1062–74. Google Scholar 2 Cattaneo A, Biocca S. Intracellular antibodies: development and applications. Berlin (Germany): Springer-Verlag; 1997. p. 1–196. Google Scholar 3 Lener M, Horn IR, Cardinale A, Messina S, Nielsen UB, Rybak SM, et al. Diverting a protein from its cellular location by intracellular antibodies: the case of p21 Ras. Eur J Biochem  2000; 267: 1196–205. Google Scholar 4 Cardinale A, Filesi I, Biocca S. Aggresome formation by anti-Ras intracellular scFv fragments. The fate of the antigen-antibody complex. Eur J Biochem  2001; 268: 268–77. Google Scholar 5 Cochet O, Kenigsberg M, Delumeau I, Virone-Oddos A, Multon MC, Fridman WH, et al. Intracellular expression of an antibody fragment-neutralizing p21 Ras promotes tumor regression. Cancer Res  1998; 58: 1170–6. Google Scholar 6 Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res  2000; 6: 3081–7. Google Scholar 7 Cohen PA, Mani JC, Lane DP. Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene  1998; 17: 2445–56. Google Scholar © Oxford University Press http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JNCI: Journal of the National Cancer Institute Oxford University Press

Re: Blocking Oncogenic Ras Signaling for Cancer Therapy

Loading next page...
 
/lp/oxford-university-press/re-blocking-oncogenic-ras-signaling-for-cancer-therapy-xJtWPFpYpR

References (10)

Publisher
Oxford University Press
Copyright
© Oxford University Press
ISSN
0027-8874
eISSN
1460-2105
DOI
10.1093/jnci/94.13.1031
Publisher site
See Article on Publisher Site

Abstract

We congratulate Adjei (1) on his excellent, comprehensive, and timely review on Ras signaling and the therapeutic implications of blocking this signaling. Perhaps space constraints and a major focus on pharmacologic aspects prevented any discussion of a promising alternative approach to perturbing Ras membrane localization, namely, the diversion of intracellular trafficking by an intracellular antibody (Fig.1). After the initial formal proof of intracellular antibody expression and targeting within the cell in 1990 [see specific publication cited in (2)], this approach was successfully applied to inhibit the function of several intracellular gene products, including p21Ras (2). The p21Ras molecule appears to be particularly sensitive to intracellular antibody-mediated perturbation of its precise localization to the inner face of the plasma membrane, which is crucial for its activity. Thus, anti-Ras intracellular antibodies with cytoplasmic targeting signals have been shown to divert p21Ras from its intracellular location and to address the antigen–antibody complex to the degradative compartment of the cell (3,4). Such intracellular antibodies are effective irrespective of the epitope recognized, the binding affinity, or the mutant status of the Ras protein broadening the spectrum of intracellular antibodies with potential therapeutic usefulness. In an animal model, intratumor injection of anti-Ras intracellular antibodies expressed by an adenoviral vector resulted in a statistically significant tumor regression, despite a low efficiency of in vivo transduction (5). The striking effects on tumors in that study implicate “bystander” mechanisms that amplify the direct inhibitory activity of the intracellular antibodies. Anti-erbB-2 [see references cited in (6)] and p53 (7) intracellular antibodies targeted, respectively, to endoplasmic reticulum and to cytoplasm/nucleus have been validated in several preclinical in vitro models as selective and potent antitumor agents. Furthermore, adenoviral constructs expressing anti-erbB-2 intracellular antibody demonstrated in vivo antitumor activity leading to prolongation of survival in ovarian cancer animal models; these constructs were recently used in a phase I trial to determine the safety profile and gene transfer efficacy after intraperitoneal administration in ovarian cancer patients (6). Rational approaches to engineering antibody regions suited for optimal expression in the desired intracellular compartment, together with improved vector design and strategies that engage bystander mechanisms, hold the promise of enhancing the feasibility and efficacy of intracellular antibody gene therapy. In conclusion, the high level of specificity observed in preclinical studies and the very limited side effects reported in the first clinical application of intracellular antibody technology (6) suggest the value of increased efforts to fully explore the clinical utility of intracellular antibodies directed against p21Ras or other oncogenic molecules. These reagents might be used alone or in combination with other selective inhibitors of oncogene signaling such as farnesyl/geranylgeranyl transferase [see (1) for details] or tyrosine kinase inhibitors. Fig. 1. View largeDownload slide Intracellular antibody expression in mammalian cells. A) The overall intracellular antibody structure, where a heavy chain variable region (VH) of an antibody connected by a linker to its complementary light chain variable region (VL) (single chain Fv = scFv) is tailed or preceded at the C terminus or N terminus, respectively, by a short targeting signal. B) The presence/absence and the amino acid sequences of some common C-terminal and N-terminal targeting signals (2). These signals allow localization of the intracellular antibody to the nucleus (n), endoplasmic reticulum (er), mitochondria (m), or cytoplasm (c), or to be secreted (s), without affecting the specific binding of the scFv to its target molecule. * = The targeting signal for nuclear localization could be either at the C terminus or at the N terminus. C) Scheme of intracellular antibody compartmentalization mediated by the defined targeting signals. Fig. 1. View largeDownload slide Intracellular antibody expression in mammalian cells. A) The overall intracellular antibody structure, where a heavy chain variable region (VH) of an antibody connected by a linker to its complementary light chain variable region (VL) (single chain Fv = scFv) is tailed or preceded at the C terminus or N terminus, respectively, by a short targeting signal. B) The presence/absence and the amino acid sequences of some common C-terminal and N-terminal targeting signals (2). These signals allow localization of the intracellular antibody to the nucleus (n), endoplasmic reticulum (er), mitochondria (m), or cytoplasm (c), or to be secreted (s), without affecting the specific binding of the scFv to its target molecule. * = The targeting signal for nuclear localization could be either at the C terminus or at the N terminus. C) Scheme of intracellular antibody compartmentalization mediated by the defined targeting signals. References 1 Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst  2001; 93: 1062–74. Google Scholar 2 Cattaneo A, Biocca S. Intracellular antibodies: development and applications. Berlin (Germany): Springer-Verlag; 1997. p. 1–196. Google Scholar 3 Lener M, Horn IR, Cardinale A, Messina S, Nielsen UB, Rybak SM, et al. Diverting a protein from its cellular location by intracellular antibodies: the case of p21 Ras. Eur J Biochem  2000; 267: 1196–205. Google Scholar 4 Cardinale A, Filesi I, Biocca S. Aggresome formation by anti-Ras intracellular scFv fragments. The fate of the antigen-antibody complex. Eur J Biochem  2001; 268: 268–77. Google Scholar 5 Cochet O, Kenigsberg M, Delumeau I, Virone-Oddos A, Multon MC, Fridman WH, et al. Intracellular expression of an antibody fragment-neutralizing p21 Ras promotes tumor regression. Cancer Res  1998; 58: 1170–6. Google Scholar 6 Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, et al. A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res  2000; 6: 3081–7. Google Scholar 7 Cohen PA, Mani JC, Lane DP. Characterization of a new intrabody directed against the N-terminal region of human p53. Oncogene  1998; 17: 2445–56. Google Scholar © Oxford University Press

Journal

JNCI: Journal of the National Cancer InstituteOxford University Press

Published: Jul 3, 2002

There are no references for this article.